+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Next-Generation Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Next-Generation Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
New

Next-Generation Cancer Diagnostics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5311174
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The next-generation cancer diagnostics market is entering a pivotal phase, shaped by rapid technology evolution and the rising demands of clinicians, payers, and research leaders. Stakeholders navigating this space require nuanced strategic intelligence to make well-informed investment, procurement, and partnership decisions that yield lasting value.

Market Snapshot: Next-Generation Cancer Diagnostics

The Next-Generation Cancer Diagnostics Market demonstrated significant growth, expanding from USD 15.03 billion in 2025 to USD 18.47 billion in 2026. It is projected to reach USD 71.55 billion by 2032 with a compound annual growth rate of 24.95%. Investment flows continue into high-throughput sequencing, molecular assay development, and advanced data analytics. These drivers are enabling health systems and research centers to move towards increased precision and actionable results in cancer diagnostics, with stakeholders prioritizing technologies that enhance early detection and therapy selection.

Scope & Segmentation

  • Product Categories: Instruments—including analyzers and sequencers—reagents and consumables critical for high-throughput and multiplex assays, and dedicated software platforms and services supporting clinical workflow integration.
  • Technology Platforms: Solutions span DNA microarrays, lab-on-a-chip systems, reverse transcriptase PCR, next-generation sequencing, protein microarrays, and multiplexed quantitative PCR, each advancing the sensitivity and versatility of diagnostic applications.
  • Cancer Types: Comprehensive solutions address biomarker needs across breast, colorectal, lung, prostate, and a range of solid and hematologic malignancies, enhancing personalized diagnostic and treatment pathways.
  • Functional Segmentation: Core areas include biomarker discovery, circulating tumor cell analysis, genetic and epigenetic assessment, and proteomic profiling, supporting both research innovation and clinical testing.
  • Staging and Application: Use cases range from early detection and progressive staging to cancer screening, companion diagnostics, prognostics, risk assessment, and ongoing monitoring of therapeutic outcomes.
  • End-User Segments: The primary adopters are diagnostic laboratories, hospitals, academic research centers, and governmental institutes, each bringing distinct procurement policies and requirements for quality validation.
  • Geographic Regions: The Americas emphasize strong reimbursement models and IT integration; Europe, Middle East & Africa feature diverse regulatory and clinical delivery frameworks; Asia-Pacific regions focus on rapid urban adoption, scalable local manufacturing, and technology localization.

Key Takeaways

  • Advances in genomics, proteomics, and digital diagnostics are streamlining workflows and empowering earlier, more precise clinical interventions.
  • Decision-makers value platforms offering interoperability and rapid result delivery, while health systems prioritize technologies that enhance measurable patient outcomes and demonstrate clear value.
  • Reduction in process complexity enables broader adoption outside specialty laboratories, fostering accessibility in decentralized clinical environments and supporting point-of-care deployment.
  • R&D alliances involving diagnostics companies, pharmaceutical developers, and clinical institutions are speeding up biomarker validation and supporting timely translation into routine care.
  • Organizations best positioned for growth incorporate modular system architecture, proactive regulatory planning, and strong partner networks into their operational strategy.

Tariff Impact on Supply Chains and Procurement

  • Higher tariffs on core reagents and capital equipment are raising input costs and elongating lead times, prompting procurement leaders to diversify their supplier base and maintain larger inventory reserves.
  • Manufacturers are evaluating near-shore and regional production strategies, as well as qualifying alternative consumables, to ensure supply stability and minimize dependency risk.
  • Flexible commercial arrangements, such as long-term pricing contracts and bundled support services, are being adopted to counter tariff-induced market volatility and maintain strong client engagement.

Rigorous Methodology & Data Sources

This report utilizes insights from direct interviews with laboratory directors, clinicians, procurement and regulatory professionals, and technology developers. These findings are supported by comprehensive literature analysis and cross-verified with peer-reviewed research and current regulatory standards to ensure robust accuracy.

Why This Report Matters

  • Informs decisions around prioritizing technology investments, platform flexibility, and cross-sector partnerships to secure long-term market differentiation.
  • Enables assessment of commercial opportunities by delivering clarity on payer, regulatory, and infrastructure factors across global markets.
  • Facilitates optimization of supply chain models and contracting strategies, minimizing procurement risk, and strengthening service reliability.

Conclusion

Next-generation cancer diagnostics are reshaping how clinical and commercial leaders navigate patient care and operational growth. Integrated approaches that blend evidence, partnerships, and agile supply chain models will determine the pace and scale of future market adoption.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Next-Generation Cancer Diagnostics Market, by Product
8.1. Instruments
8.1.1. Analyzers
8.1.2. Sequencers
8.2. Reagents & Consumables
8.3. Software & Services
9. Next-Generation Cancer Diagnostics Market, by Technology
9.1. DNA Microarrays
9.2. Lab-on- a- chip & Reverse Transcriptase-PCR
9.3. Next-generation Sequencing
9.4. Protein Microarrays
9.5. qPCR & Multiplexing
10. Next-Generation Cancer Diagnostics Market, by Cancer Type
10.1. Breast Cancer
10.2. Colorectal Cancer
10.3. Lung Cancer
10.4. Prostate Cancer
11. Next-Generation Cancer Diagnostics Market, by Function
11.1. Biomarker Development
11.2. CTC Analysis
11.3. Epigenetic Analysis
11.4. Genetic Analysis
11.5. Proteomic Analysis
12. Next-Generation Cancer Diagnostics Market, by Staging
12.1. Early Detection
12.2. Progressive Staging
13. Next-Generation Cancer Diagnostics Market, by Application
13.1. Cancer Screening
13.2. Companion Diagnostics
13.3. Prognostics
13.4. Risk Assessment
13.5. Therapeutic Monitoring
14. Next-Generation Cancer Diagnostics Market, by End-User
14.1. Diagnostic Laboratories
14.2. Hospitals
14.3. Research Institutes
14.3.1. Academic
14.3.2. Governmental
15. Next-Generation Cancer Diagnostics Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Next-Generation Cancer Diagnostics Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Next-Generation Cancer Diagnostics Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Next-Generation Cancer Diagnostics Market
19. China Next-Generation Cancer Diagnostics Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Abbott Laboratories
20.6. Adaptive Biotechnologies Corporation
20.7. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
20.8. Agilent Technologies, Inc.
20.9. Akadeum Life Sciences
20.10. Almac Group
20.11. Becton, Dickinson & Company
20.12. Bio-Techne Corporation
20.13. Biological Dynamics Inc.
20.14. bioMérieux SA
20.15. BioNTech SE
20.16. Castle Biosciences Inc.
20.17. Danaher Corporation
20.18. Exact Sciences Corporation
20.19. F. Hoffmann-La Roche Ltd.
20.20. GE HealthCare
20.21. Hologic Inc.
20.22. Illumina, Inc.
20.23. Johnson & Johnson Services, Inc.
20.24. Konica Minolta, Inc.
20.25. Koninklijke Philips N.V.
20.26. NeoGenomics Laboratories
20.27. Novartis AG
20.28. OPKO Health, Inc.
20.29. Oxford Nanopore Technologies Limited
20.30. Perkin Elmer, Inc.
20.31. Qiagen N.V.
20.32. Siemens Healthineers AG
20.33. Sysmex Corporation
20.34. Telerad Tech
20.35. Thermo Fisher Scientific, Inc.
List of Figures
FIGURE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 145. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 147. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 152. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 153. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 154. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 165. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 167. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 168. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 169. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 170. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 171. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 172. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 174. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 188. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 189. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 192. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 193. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 195. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 196. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 198. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 199. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 200. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 201. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 202. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 203. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 204. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 205. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 216. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 218. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 219. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 220. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 221. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 222. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 223. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 224. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 225. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 226. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 227. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 228. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 229. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 230. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 231. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 232. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 233. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 234. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 235. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 236. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 238. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 239. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 240. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 241. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 242. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 243. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 244. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 245. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 246. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
TABLE 257. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 259. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 260. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 261. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 262. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
TABLE 263. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
TABLE 264. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 265. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 266. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Next-Generation Cancer Diagnostics market report include:
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Almac Group
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • Biological Dynamics Inc.
  • bioMérieux SA
  • BioNTech SE
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • NeoGenomics Laboratories
  • Novartis AG
  • OPKO Health, Inc.
  • Oxford Nanopore Technologies Limited
  • Perkin Elmer, Inc.
  • Qiagen N.V.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Telerad Tech
  • Thermo Fisher Scientific, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 18.47 Billion
Forecasted Market Value ( USD ) by 2032 $ 71.55 Billion
Compound Annual Growth Rate24.9%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Next-Generation Breast Cancer Diagnostic & Screening Market - Global Forecast 2026-2032 - Product Image

Next-Generation Breast Cancer Diagnostic & Screening Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market - Global Forecast 2026-2032 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), Application, Cancer Type, Function, and Region with Growth Forecasts, 2025-2033 - Product Image

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Next Generation Sequencing, qPCR & Multiplexing, DNA Microarrays), Application, Cancer Type, Function, and Region with Growth Forecasts, 2025-2033

  • Report
  • 138 Pages
  • Global
From
Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities - Product Image

Cancer Diagnostics Market - Technologies, Applications and End-Use Facilities

  • Report
  • 278 Pages
  • Global
From
Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033 - Product Image

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033

  • Report
  • 145 Pages
  • Global
From

About the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is a subset of the Diagnostics industry that focuses on the development of advanced technologies for the early detection and diagnosis of cancer. These technologies include molecular diagnostics, biomarkers, imaging, and other methods that can detect cancer at its earliest stages. This market is driven by the need for more accurate and timely diagnosis of cancer, as well as the increasing prevalence of the disease. The Next Generation Cancer Diagnostics market is expected to grow significantly in the coming years, driven by the increasing demand for early diagnosis and the development of new technologies. This market is also expected to benefit from the increasing availability of data and the development of artificial intelligence and machine learning. Some of the major players in the Next Generation Cancer Diagnostics market include Illumina, Thermo Fisher Scientific, Roche, Qiagen, and Agilent Technologies. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.